193 related articles for article (PubMed ID: 8811211)
1. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
2. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
4. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
6. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
7. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
8. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.
Cathomas R; Klingbiel D; Geldart TR; Mead GM; Ellis S; Wheater M; Simmonds P; Nagaraj N; von Moos R; Fehr M
Ann Oncol; 2014 Aug; 25(8):1591-7. PubMed ID: 24669017
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of six radionuclidic and non-radionuclidic methods for the assessment of glomerular filtration rate in patients with chronic renal failure].
Fotopoulos A; Bokharhli JA; Tsiouris S; Katsaraki A; Papadopoulos A; Tsironi M; Theodorou J
Hell J Nucl Med; 2006; 9(2):133-40. PubMed ID: 16894423
[TBL] [Abstract][Full Text] [Related]
10. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
[TBL] [Abstract][Full Text] [Related]
12. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
Chinnaswamy G; Cole M; Boddy AV; Keir M; Price L; Parry A; English M; Veal GJ;
Br J Cancer; 2008 Sep; 99(6):894-9. PubMed ID: 18781149
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
[TBL] [Abstract][Full Text] [Related]
14. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
16. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
Adamson PC; Veal GJ; Womer RB; Meany HJ; Bernhardt MB; Frazier AL; Balis FM
Pediatr Blood Cancer; 2019 Jun; 66(6):e27672. PubMed ID: 30767382
[TBL] [Abstract][Full Text] [Related]
17. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Bailey DB; Rassnick KM; Erb HN; Dykes NL; Hoopes PJ; Page RL
Am J Vet Res; 2004 Nov; 65(11):1502-7. PubMed ID: 15566088
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.
McLean L; Whittle JR; Graham J; Ismail H; Lichtenstein M; Hicks RJ; McNally O; Herschtal A; Rosenthal M; Rischin D; Hamilton A
Gynecol Oncol; 2020 Jun; 157(3):793-798. PubMed ID: 32220419
[TBL] [Abstract][Full Text] [Related]
19. Estimation of glomerular filtration rate in cancer patients.
Wright JG; Boddy AV; Highley M; Fenwick J; McGill A; Calvert AH
Br J Cancer; 2001 Feb; 84(4):452-9. PubMed ID: 11207037
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
